On July 21, 2026 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, reported that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the event are as follows:
Date: Tuesday, August 11, 2026
Time: 10:30 a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.

(Press release, Adicet Bio, JUL 21, 2026, View Source [SID1234669351])

On July 21, 2026 AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, reported that updated clinical results from the Phase 1b TheraPb trial (NCT05720130) evaluating 212Pb-ADVC001 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) have been accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, held October 23–27, 2026, in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will include updated results from the dose-escalation portion of the TheraPb study. The data represents the first long-term follow-up of a targeted alpha therapy study employing a novel design escalating both administered activities and dose schedules, supporting the recommended Phase 2 dose and regimen. The presentation builds on previously reported encouraging Phase 1b data and supports the continued clinical development of 212Pb-ADVC001, currently enrolling Phase 2 evaluating a novel dosing regimen of intensified induction and adaptive dosing strategies.

ESMO 2026 Presentation Details

Title: Updated Results from the TheraPb Trial Defining the Recommended Phase 2 Dose (RP2D) of 212Pb-ADVC001 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Presentation Number: 2253P

Presentation Type: Poster Presentation

Location: Madrid, Spain

Date/Time: 23 October 2026 / 3:15 – 4:00 PM CET

(Press release, Advancell, JUL 21, 2026, View Source [SID1234669350])

On July 21, 2026 Pilatus Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, reported that the Hong Kong Department of Health has granted the Certificate for Clinical Trial / Medicinal Test for lead investigational therapy, PLT012 in patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study will be conducted at the Phase I Clinical Trial Centre, under the Department of Clinical Oncology of The Chinese University of Hong Kong. The regulatory approval authorizes Pilatus to initiate a clinical trial evaluating PLT012 in Hong Kong, and represents an important milestone in advancing the Company’s global clinical development program to advance the novel therapy for patients with advanced solid tumors, including liver cancer and gastrointestinal cancers.

Pilatus also announced the establishment of its Hong Kong subsidiary, expanding its presence in one of Asia’s leading biotechnology and clinical-research hubs. The company has worked closely with Invest Hong Kong (InvestHK) to establish its regional operations and plans to leverage Hong Kong’s growing life sciences ecosystem to support clinical development, academic and strategic collaborations, and engagement with regional investment opportunities.

"We are pleased to receive CTA approval, which enables the PLT012 clinical study to commence in Hong Kong. We look forward to working with the study team to evaluate the safety and clinical potential of this investigational therapy in patients with advanced solid tumors," said Dr. Stephen Chan, principal study investigator and clinical professor at the Department of Clinical Oncology of The Chinese University of Hong Kong.

"We are pleased to establish our presence in Hong Kong as we continue executing our global development strategy," said Raven Lin, CEO & Co-founder, Pilatus Biosciences. "Hong Kong offers a world-class clinical research environment, a strong regulatory framework, and a growing biotechnology ecosystem. We appreciate the support of InvestHK and look forward to becoming an active participant in Hong Kong’s innovation ecosystem while advancing PLT012 toward the clinic."

PLT012 is a first-in-class therapeutic targeting CD36, a key regulator of metabolic dysfunction and inflammation. The program is being developed for indications where modulation of CD36 has the potential to improve patient outcomes.

The establishment of Pilatus’ Hong Kong operations strengthens the Company’s presence in Asia, enabling deeper regional collaborations, accelerating clinical development, and expanding engagement with investors and strategic partners.

About PLT012

PLT012 is a humanized monoclonal antibody designed to selectively block CD36-mediated lipid uptake, a key mechanism driving immunosuppression and immune exclusion within the tumor microenvironment. By targeting lipid metabolism, PLT012 exerts a unique mechanism of action: it depletes immunosuppressive cell populations, including Tregs and pro-tumor macrophages, while simultaneously enhancing antitumor activities of intratumoral NK cell and cytotoxic CD8+ T cell that are otherwise susceptible to lipid-induced exhaustion. In preclinical studies, PLT012 has demonstrated potent monotherapy efficacy in models of liver malignancies, with a favorable safety profile across species. Leveraging its distinct mechanism of action, PLT012 further acts as a potent sensitizer in combination with anti–PD-L1 therapies, effectively overcoming drug resistance in immune "cold" tumors and liver metastases.

(Press release, Pilatus Biosciences, JUL 21, 2026, View Source [SID1234669349])

On July 21, 2026 Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation macrophage-directed immunotherapies for cancer, reported a peer-reviewed publication in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), detailing the preclinical foundation for its lead program, PHST001, a novel, high-affinity IgG4 anti-CD24 monoclonal antibody currently in Phase 1 clinical development for multiple solid tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The published findings demonstrate that PHST001 binds CD24 with high affinity, blocks CD24-Siglec-10 signaling, and drives macrophage phagocytosis of tumor cells. PHST001 showed robust anti-tumor activity across six solid tumor models — ovarian, breast, endometrial, pancreatic, lung, and cholangiocarcinoma — and enhanced the effects of chemotherapy, radiotherapy, and antibody-drug conjugates, including in treatment-resistant tumor models. The findings also reveal crucial crosstalk between the adaptive immune system and macrophages activated by PHST001.

"Cancer cells survive in part by expressing cell surface ‘don’t eat me’ signals that suppress critical immune surveillance functions of the immune system’s macrophages. CD24 is one of the most important of these signals expressed on several types of human cancer cells; this publication shows that blocking it with PHST001 can mobilize macrophages against a broad range of solid tumors," said Irving Weissman, M.D., co-founder of Pheast Therapeutics. "This is a significant advance for the field of innate immune therapy against cancer and is critical for the next stages to determine the potential of PHST001 to become an important new cancer treatment."

"The combination benefit outlined in this publication is exactly what we are now testing in patients, where PHST001 has already shown promising early signs of activity," said Roy Maute, Ph.D., co-founder and Chief Executive Officer of Pheast. "These peer-reviewed data underpin our conviction in CD24 as a critical target and Pheast’s leadership in macrophage checkpoint immunotherapy."

PHST001 is being evaluated in the ongoing Phase 1 PHST001-101 trial (NCT06840886) in patients with relapsed or refractory solid tumors. The monotherapy dose-escalation is nearly complete, and the chemotherapy combination cohorts are underway. Pheast expects to present initial clinical data at an upcoming medical meeting. PHST001 received FDA Fast Track Designation for the treatment of ovarian cancer in June 2025.

The Clinical Cancer Research publication is available here: View Source

About CD24

CD24 is a cell surface protein that plays a key role in tumor immune evasion by engaging Siglec-10, an inhibitory receptor on macrophages. This interaction suppresses macrophage-mediated clearance of cancer cells, allowing tumors to escape destruction by the innate immune system. CD24 was identified as a novel macrophage checkpoint through foundational work by Dr. Amira Barkal, principal founder of Pheast. Along with other co-founders, Drs. Irving Weissman, Ravi Majeti, and Roy Maute, Pheast’s research opened the door to therapeutic strategies targeting CD24 to drive innate immune responses against cancer.

About PHST001

PHST001 is an anti-CD24 macrophage checkpoint inhibitor designed to overcome immune suppression in the tumor microenvironment. CD24 is highly expressed across many cancers, where high expression is associated with poor prognosis. Pheast has engineered PHST001 to be a potential best-in-class antibody designed to induce macrophages to phagocytose cancer cells and initiate a powerful immune response. PHST001-101 is an open-label, multicenter Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT06840886) evaluating safety, tolerability, and dose optimization, with secondary objectives assessing pharmacokinetics and preliminary anti-tumor activity. PHST001 received FDA Fast Track Designation for the treatment of ovarian cancer in June 2025.

(Press release, Pheast Therapeutics, JUL 21, 2026, View Source [SID1234669348])

On July 21, 2026 Tract Bio ("Tract"), a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, reported presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Drug Discovery and Development (AACR D3) conference and the AACR (Free AACR Whitepaper) Special Conference on Breaking Barriers in the Fight Against Rare Cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tract is advancing complementary approaches aimed at the drug-resistant cancer stem cells (CSCs) that survive treatment and drive disease progression. The stemECHO platform selectively clones CSCs while preserving genomic and epigenomic fidelity, enabling functional screening to identify the drugs that eliminate them in an individual patient; TP101 is a small molecule therapeutic candidate that has been tested against these cells directly.

"Cancer stem cells drive tumor progression and therapeutic resistance yet have been difficult to eliminate selectively. Our functional precision medicine approach has the potential to find these cells and the drugs that eliminate them in an individual patient with ovarian cancer, and TP101 demonstrates how we can develop therapeutics against them directly while preserving normal stem cells," said Dr. Frank McKeon, Chief Scientific Officer and Co-Founder of Tract Bio. "We are encouraged by the TP101 data which we believe support its potential as a new treatment approach for Barrett’s esophagus, esophageal adenocarcinoma, and high-grade epithelial malignancies, and we are continuing to advance toward an IND submission."

AACR Drug Discovery and Development (AACR D3): July 21-24, 2026; Boston, MA

The poster presentation highlights TP101, a first-in-class small molecule therapeutic that combines a proprietary bivalent IAP antagonist and the tyroskine kinase inhibitor ponatinib to selectively eliminate CSCs across epithelial solid tumors while sparing healthy epithelial stem cells. The dual small molecule combination killed CSCs in vitro with low nanomolar potency, robust caspase 3 activation, and marked sparing of normal esophageal stem cells in Barrett’s esophagus and esophageal adenocarcinoma (EAC). In mouse xenografts, TP101 drove near-complete tumor regression of EAC and depletion of tumor-associated fibroblasts. Together, these data support TP101 as a therapeutic strategy to potently and selectively eliminate malignant stem cells while targeting tumor supportive stroma and broadening the therapeutic window.

Presentation details are as follows:

Title: TP101: First-in-class cancer stem cell–targeted small molecule combination therapy for epithelial malignancies
Presenters: Cody C. McHale, Ph.D., Chief Operating Officer of Tract Bio; Souneek Chakraborty, Ph.D., Principal Scientist, Biology of Tract Bio
Session Date and Time: Poster #A078, Session A – Wednesday, July 22, 2026, 6:15-8:45 p.m. ET
Venue: Sheraton Boston Hotel, Back Bay Ballroom
AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers: July 18-20, 2026; Vancouver, British Columbia

The second poster highlights a functional precision medicine approach in high-grade serous ovarian cancer, leveraging the Company’s stemECHO platform to clone cancer stem cells from individual patient specimens. Tract researchers identified a polyresistant population in every case examined, then screened those cells against hundreds of approved and investigational drugs to find combinations that eliminated them at low nanomolar concentrations in vitro and showed activity in xenograft models derived from the polyresistant clones. This approach has the potential to deliver patient-specific drug sensitivity profiles to a multidisciplinary Functional Precision Medicine Tumor Board within 14 to 28 days of biopsy receipt.

Title: Functional precision medicine targeting polyresistant cancer stem cells in high-grade serous ovarian cancer
Presenters: Wa Xian, Ph.D., Chief Scientific Officer and Co-Founder of Tract Bio; Yen-hsiang "Johnson" Huang, Senior Bioinformatics Scientist of Tract Bio
Session Date and Time: Poster #A030, Session A – Saturday, July 18, 2026, 7:30-9:30 p.m. PDT
Venue: JW Marriott Parq Vancouver Hotel, Vancouver, BC, Canada

(Press release, Tract Bio, JUL 21, 2026, View Source [SID1234669347])